As per MRFR Analysis, the Ischemic Stroke Market was valued at 4.92 USD Billion in 2024 and is projected to grow to 9.80 USD Billion by 2034, with a CAGR of 7.13% from 2025 to 2034. The market growth is driven by factors such as increased health consciousness, rising diabetes prevalence, tobacco use, and an aging population. Recent research highlights uric acid as a potential therapy for improving recovery from acute ischemic stroke, warranting further investigation. The market is characterized by a high prevalence of ischemic stroke globally, with significant mortality rates attributed to cerebrovascular diseases. North America leads the market, followed by Europe and Asia-Pacific, with CT scans being the most utilized diagnostic method and antiplatelet drugs holding the largest market share in treatment options.
The Ischemic Stroke market is witnessing significant growth driven by various factors.
Fujifilm Holdings Corporation, GE Healthcare, Siemens Healthcare, Samsung Electronics Co. Ltd, Koninklijke Philips NV, and others.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
September 2023: Researchers have recognized uric acid as a potential therapy to improve recovery from acute ischemic stroke, utilizing the latest technique for carrying out preclinical animal research. In this case, researchers from the National Institutes of Health's Stroke Preclinical Assessment Network (SPAN) thoroughly tested the effectiveness of six novel therapies in lowering ischemic brain injury in rodents utilizing strategies routinely reserved for clinical studies in humans. The results imply that uric acid warrants additional investigation in additional studies and possibly human clinical trials.
The study was published in Science Translational Medicine). A prominent cause of disability and death in the United States, Ischemic stroke appears when a blood clot or other blockage in an artery cuts off blood supply to the brain. Present treatments are focused on eliminating the clot by closing it with blood thinners, surgically eradicating it from the blood vessel or a combination of both.
Although these treatments help patients recover, scientists are looking for a therapy that could safeguard the brain from damage, called a cerebroprotectant, appearing before or during the rebuilding of blood flow. Although former preclinical studies in animals have recognized several confirming therapies, they failed to translate to human stroke patients in succeeding clinical trials. Many findings also were not replicated in other laboratories.
April 2024: An ambitious, worldwide clinical trial led by UVA Health's Karen Johnston, MD, has offered doctors long-needed insights into the consequence of managing stroke patients' blood sugar after treatment with clot-busting therapy. The results will assist in enhancing stroke care and save lives. The SHINE trial, backed by the National Institutes of Health's National Institute of Neurological Disorders and Stroke, was carried out at UVA Health and 69 other hospitals around the country.
The rising global prevalence of ischemic stroke is projected to drive ischemic stroke market growth. This is owing to an increase in the incidence of ischemic stroke, which is being ascribed to a variety of factors including an ageing population, sedentary lifestyles, bad eating habits, and the rising prevalence of risk factors such as hypertension, diabetes, and obesity. Furthermore, developments in medical technologies and treatment alternatives are projected to fuel market expansion.
For instance, as per the 2021 Heart Disease & Stroke Statistical Update Fact Sheet provided by the American Heart Association, the global prevalence of stroke in 2019 was 101.5 million people, while that of ischemic stroke was 77.2 million. Overall, age-standardized stroke prevalence rate in 2019 was highest in Oceania, Southeast Asia, North Africa, and the Middle East, as well as East Asia.
Countries in parts of North Africa and the Middle East, Southern sub-Saharan Africa, high-income countries in North America and Southeast Asia had the highest ischemic stroke prevalence rate. Furthermore, in 2019, there were 6.6 million deaths worldwide due to cerebrovascular diseases. In 2019, a total of 3.3 million people worldwide died from ischemic stroke, 2.9 million died from intracerebral hemorrhage, and 0.4 million died from subarachnoid hemorrhage.
These factors are projected to fuel Ischemic Stroke market revenue expansion in the next years and improve market CAGR across the globe in the recent years.
The market segments of Ischemic Stroke, based on Diagnosis, includes CT, MRI, Carotid Ultrasound, and Cerebral Angiography. In 2022, the CT category has the greatest market share in the worldwide ischemic stroke market. Because of its short turnaround time and ability to see the brain anatomy in detail, CT is commonly utilized for diagnosing ischemic stroke. CT is significantly less expensive than MRI, making it more affordable to patients in developing countries.
Several businesses have created CT scanners that use lower radiation doses, potentially lowering the risk of cancer and other radiation-related side effects.
September 2021: Siemens Healthineers, for example, announced the launching of the SOMATOM X.ceed CT scanner in September 2021, which employs innovative algorithms to limit radiation exposure without affecting image quality.
The global Ischemic Stroke market segmentation, based on Drug Class, includes Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive. In 2022, The antiplatelet category has the biggest market share in the worldwide market growth of ischemic stroke. This is because antiplatelet medications are often used as a first-line treatment for ischemic stroke since they help prevent blood clot formation and minimize the risk of subsequent strokes. Antiplatelet medications like aspirin and clopidogrel are commonly used to prevent and treat ischemic stroke.
FIGURE 1: ISCHEMIC STROKE MARKET, BY DRUG CLASSS, 2025 & 2034 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Ischemic Stroke market dominated in 2022, followed by Europe and the Asia-Pacific. North America Ischemic Stroke dominated the market owing to favorable government initiatives, technical breakthroughs, and increased demand for ischemic stroke solutions.
Furthermore, prominent market players are focusing on inorganic growth tactics such as acquisitions and partnerships to expand their product portfolio and presence in the worldwide acute ischemic stroke (AIS) market. For example, AstraZeneca, a global, science-led biopharmaceutical company, announced the November 2020 launch of Brilinta (an oral, reversible, direct-acting P2Y12 receptor antagonist), which is used to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack (TIA).
Furthermore, the rising occurrence of stroke in North America propels market expansion. According to the American Heart Association 2022, cardiovascular disease (CVD) was acknowledged as the leading cause of death in the United States in 2019, accounting for 874,613 fatalities. Furthermore, according to Dawn O. Kleindorfer's research published in the American Heart Association Journal in May 2021, 795 000 people in the United States have a stroke each year, with 87% (690 000) being ischemic and 185 000 being recurrent. Almost 240,000 people suffer from a transient ischemic stroke each year (TIA). As a result, the country's rising prevalence of cardiovascular illnesses and stroke is likely to drive the acute ischemic stroke diagnosis market.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: ISCHEMIC STROKE MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The European ischemic stroke market accounts for a sizable portion of the worldwide market of Ischemic Stroke. Europe has a big and ageing population that is predisposed to ischemic stroke due to variables such as hypertension, high cholesterol, diabetes, and smoking. The European ischemic stroke market is predicted to increase at a CAGR of 5.2% from 2024 to 2030. The region's increasing frequency of ischemic stroke, combined with a growing awareness of the need of early diagnosis and treatment, is likely to fuel market growth. Further, the Germany market of Ischemic Stroke held the largest market share, and the UK market of Ischemic Stroke was the fastest growing market in the European region
The Asia-Pacific ischemic stroke market is expanding as a result of a number of factors, including rising ischemic stroke incidence and prevalence, improved healthcare infrastructure and treatment availability, and rising healthcare expenditure in the region. The Asia-Pacific area is rapidly ageing, with several countries expecting a substantial share of senior citizens in the future decades. Because age is a major risk factor for ischemic stroke, this demographic shift has been connected to an increased incidence of the disorder.
Furthermore, the region is seeing an increase in lifestyle-related risk factors such hypertension, diabetes, and smoking, which raises the risk of ischemic stroke. Moreover, the region's growing healthcare infrastructure and availability to treatment are fueling market expansion. Many Asian countries are actively investing in their healthcare systems, which has resulted in increased diagnosis and treatment capacities.
Furthermore, the increased availability of advanced medical technologies such as CT and MRI scanners, as well as an increase in the number of stroke centers and neurologists, has made it simpler for patients to receive early and effective treatment. Moreover, China market of Ischemic Stroke held the largest market share, and the India market of Ischemic Stroke was the fastest growing market in the Asia-Pacific region.
Ischemic Stroke Key Market Players & Competitive Insights
The market of Ischemic Stroke is highly competitive, with several major market players operating in the market. Market participants are also pursuing a variety of market developments to expand their global footprint, including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other companies. Competitors in the Ischemic Stroke industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
The Ischemic Stroke market major player such as Fujifilm Holdings Corporation, Samsung Electronics Co. Ltd, GE Healthcare, Siemens Healthcare, Kohden Corporation, Koninklijke Philips NV, and Others.
Fujifilm Holdings Company is a Japanese multinational conglomerate headquartered in Tokyo. The company operates in a variety of industries, including imaging, information solutions, and document solutions. Fujifilm's portfolio includes healthcare-related products and services such as medical imaging equipment, diagnostics, and regenerative medicine. Fujifilm provides a variety of goods and services for the diagnosis and treatment of ischemic stroke in the market.
Medical imaging equipment from the company, such as the Synapse Picture Archiving and Communication System (PACS), is utilised for the visualisation and processing of brain pictures, which can aid in the diagnosis and management of ischemic stroke. Fujifilm also provides ischemic stroke diagnostic instruments, such as the FCT Embrace and FDR Go PLUS computed tomography (CT) scanners.
GE Healthcare is a multinational conglomerate headquartered in Chicago, Illinois, United States. The company is a major provider of medical technologies and solutions, focusing on improving healthcare outcomes through advanced diagnostic and therapeutic products. GE Healthcare provides a variety of products and services for the diagnosis and treatment of ischemic stroke in the market. Medical imaging technology from the company, such as its Optima CT and Discovery MR scanners, can help with the diagnosis of ischemic stroke by providing detailed images of the brain.
GE Healthcare also provides a variety of diagnostic tools for ischemic stroke, such as their CT Perfusion software, which can assist clinicians in determining the extent of brain damage caused by a stroke in a timely and accurate manner.
Key Companies in the Ischemic Stroke market includes
Ischemic Stroke Industry Developments
Feb 2022: CERENOVUS, a subsidiary of Johnson & Johnson Medical Devices Company, has introduced EMBOGUARD, a next-generation balloon guide catheter for use in endovascular treatments, particularly those for patients with acute ischemic stroke.
October 2021: With the release of the pRESET 6-50 mechanical thrombectomy device for the treatment of acute large vascular occlusive (LVO) stroke, Phenox expanded its technology portfolio.
| Attribute/Metric | Details |
| Market Size 2024 | 4.92 (USD Billion) |
| Market Size 2025 | 5.27 (USD Billion) |
| Market Size 2034 | 9.80 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 7.13 % (2025 - 2034) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2034 |
| Historical Data | 2020 - 2024 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Diagnosis, Drug Class, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Fujifilm Holdings Corporation, Samsung Electronics Co. Ltd, GE Healthcare, Siemens Healthcare, Kohden Corporation, Koninklijke Philips NV, and Others. |
| Key Market Opportunities | Increased focus on research and development Expanding market in developing countries |
| Key Market Dynamics | Increasing prevalence of ischemic stroke globally Growing aging population Technological advancements in imaging and diagnostics Increasing awareness and initiatives to promote stroke prevention. Rising demand for minimally invasive surgeries |
Ischemic Stroke Market Highlights:
Frequently Asked Questions (FAQ) :
The global Ischemic Stroke market size was valued at USD 4.0 Billion in 2022.
The global market is projected to grow at a CAGR of 7.13% during the forecast period, 2025 - 2034
North America had the largest share in the global market
The key players in the market are Fujifilm Holdings Corporation, Samsung Electronics Co. Ltd, GE Healthcare, Siemens Healthcare, Kohden Corporation, Koninklijke Philips NV, and Others.
The CT segment dominated the market in 2022.
The Antiplatelet had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
